Clinical trials
HER2-negative Breast Cancer clinical trials
Below are recruiting her2-negative breast cancer clinical trials, each written for real people, not researchers. We’re tracking 264 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04836156RecruitingPhase 1/Phase 2
Personalized pre-surgery treatment for HER2-negative early breast cancer
This study tests a treatment plan chosen using lab drug testing on a patient’s tumor (in a dish). It may help improve outcomes for people with early breast cancer that is HER2-negative by matching therapy to what the tumor seems sensitive to.
BeijingAges 18–75 - NCT06065748RecruitingPhase 3
New hormone therapy for advanced breast cancer after prior treatment
This trial tests a new oral hormone therapy, giredestrant, against a standard hormone therapy (fulvestrant) when both are given with a CDK4/6 inhibitor. It is for people with advanced ER-positive, HER2-negative breast cancer that has come back after initial hormone therapy, and who have not yet had other treatments for advanced disease.
Daphne, AlabamaAges 18 years+ - NCT04576143RecruitingPhase 2/Phase 3
Dose-dense chemo before surgery for HER2-negative breast cancer
This trial studies a faster, higher-frequency chemotherapy schedule given before surgery for HER2-negative breast cancer. It aims to see if this approach works better and is safe for the patient’s cancer stage.
Hangzhou, ZhejiangAges 18–70 - NCT06418594RecruitingPhase 2
Drug combo for HER2-negative breast cancer brain metastasis
This trial tests a combination of two drugs (adebrelimab and apatinib) plus chemotherapy for women with HER2-negative breast cancer that has spread to the brain. It aims to see if this treatment can help shrink or control brain tumors.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05305924RecruitingPhase 2
Fulvestrant plus abemaciclib for ER+, HER2− advanced breast cancer
This Phase 2 study tests whether adding abemaciclib to fulvestrant can slow or shrink ER-positive, HER2-negative metastatic breast cancer. It is mainly for people whose cancer has progressed despite prior treatment with a CDK4/6 inhibitor and an aromatase inhibitor.
Houston, TexasAges 18 years+ - NCT06179303RecruitingPhase 2
Imaging to predict response to abemaciclib for advanced breast cancer
This trial tests if a special PET scan can predict how well the drug abemaciclib works for people with advanced hormone receptor-positive, HER2-negative breast cancer. If you qualify, you would receive abemaciclib and have imaging scans to see if your cancer responds.
St Louis, MissouriAges 18 years+ - NCT05901428RecruitingPhase 3
Check if two breast cancer treatments work better after surgery
This trial compares two treatment approaches in people with high-risk hormone-positive, HER2-negative breast cancer that has spread to certain lymph nodes. It looks at which option works best to lower cancer returning and to control the disease after surgery and initial chemotherapy.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT07112053RecruitingPhase 2
Vaccine with hormone therapy or chemo for advanced breast cancer
This trial tests a vaccine (STEMVAC) given with your standard hormone therapy or chemotherapy. It is for people with advanced hormone receptor-positive, HER2-negative breast cancer who are already on certain treatments. The goal is to see if adding the vaccine can help control the cancer better.
Seattle, WashingtonAges 18 years+ - NCT07180160RecruitingPhase 2
A study of QL1706 for HR-positive, HER2-negative breast cancer
This trial tests a new drug combination (iparomlimab and tuvonralimab, also called QL1706) for people with advanced breast cancer that is hormone receptor-positive and HER2-negative. It may be an option if standard treatments have stopped working.
ShanghaiAges 18 years+ - NCT05467891RecruitingPhase 2
Ribociclib plus hormone therapy for recurrent breast cancer
This trial tests whether adding ribociclib (a targeted pill) to hormone therapy can control breast cancer that has come back in the breast area or nearby lymph nodes/chest wall. It targets hormone-receptor–positive and HER2-negative tumors to help slow disease after local treatment.
Birmingham, AlabamaAges 18 years+ - NCT07396454RecruitingPhase 2
Radiation plus anlotinib for HER2-negative breast cancer brain metastases
This trial tests whether adding anlotinib (a targeted therapy) to standard radiation can better control breast cancer that has spread to the brain. It is for people with HER2-negative breast cancer and at least one brain tumor seen on MRI.
NanjingAges 18–70 - NCT06953882RecruitingPhase 2
Skipping chemo after surgery for ER+ HER2- breast cancer
This study tests whether some people with a certain type of breast cancer (ER-positive, HER2-negative) can safely skip chemotherapy. After surgery, they receive a targeted pill (ribociclib) plus hormone therapy instead. The goal is to see if this approach works just as well with fewer side effects.
New Haven, ConnecticutAges 18 years+ - NCT06908668RecruitingPhase 2
Adebrelimab plus chemo with or without radiation before breast cancer surgery
This trial tests adding a drug called adebrelimab to standard chemotherapy and possibly radiation, given before surgery for breast cancer that is HER2-negative and locally advanced. The goal is to see if this combination helps shrink tumors more effectively, potentially allowing for breast-conserving surgery.
BeijingAges 18–70 - NCT06950086RecruitingPhase 1/Phase 2
TYK-00540 tablets for advanced solid tumors
This trial tests a new tablet, TYK-00540, alone or with another drug, for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug can shrink tumors or slow their growth.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06516289RecruitingPhase 2
Neoadjuvant treatment for BRCA-mutated HER2-negative breast cancer
This trial tests a combination of two oral medications (HRS-1167 and famitinib) with or without an immunotherapy drug (camrelizumab) before surgery for women with a BRCA gene mutation and HER2-negative breast cancer. It aims to see if these drugs can shrink tumors before surgery.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT05525767RecruitingPhase 4
Bevacizumab plus chemo before surgery for HER2-negative breast cancer
This trial studies whether adding bevacizumab (an anti-blood-vessel medicine) to chemotherapy before surgery improves treatment outcomes for people with HER2-negative breast cancer. It’s mainly for tumors that are stage II to IIIC and have not had prior cancer treatment.
Shijiazhuang, HebeiAges 18 years+ - NCT06102824RecruitingPhase 2
Organoid-guided treatment for advanced breast cancer
This trial tests whether using a miniature version of your tumor grown in a lab can help choose the best treatment for advanced breast cancer. It compares this personalized approach to standard care.
Guangzhou, GuangdongAges 18–80 - NCT05576389RecruitingPhase 2
Fluzoparib plus camrelizumab before surgery for BRCA-related HER2-negative breast cancer
This study tests a combination of two drugs – fluzoparib (a PARP inhibitor) and camrelizumab (an immunotherapy) – given before surgery for early-stage or locally advanced HER2-negative breast cancer in people with an inherited BRCA mutation. The goal is to see if this treatment can shrink the tumor and improve outcomes.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06857305Enrolling by invitationPhase 3
Eribulin every two weeks vs standard schedule for advanced breast cancer
This trial compares a new every-two-week dosing schedule of the chemotherapy drug eribulin to the standard schedule in people with HER2-negative breast cancer that has returned or spread. The goal is to see if the biweekly regimen is safer or works better.
Beijing, BAges 18 years+ - NCT06860529RecruitingPhase 2
Immunotherapy plus chemo for early-stage HR+/HER2- breast cancer
This trial tests adding the immunotherapy drug serplulimab to standard chemotherapy for people with early-stage HR-positive, HER2-negative breast cancer. It aims to see if this combination can improve outcomes before surgery.
Zhengzhou, HenanAges 18 years+ - NCT06731140RecruitingPhase 2
Reversing immune resistance in HER2-negative breast cancer
This trial tests a new treatment to see if it can reverse resistance to immunotherapy in people with HER2-negative breast cancer. It's for patients whose cancer has gotten worse after immunotherapy.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT05890287Recruiting
Chidamide plus hormone therapy after chemotherapy for breast cancer
This trial studies chidamide added to standard hormone (endocrine) therapy to help prevent breast cancer from coming back after initial chemotherapy. It may help by keeping cancer under control for longer in people with HR-positive, HER2-negative breast cancer who respond to first-line treatment.
TianjinAges 18–75 - NCT05812807RecruitingPhase 3
Pembrolizumab versus monitoring after triple-negative breast cancer response
This trial checks whether giving pembrolizumab (an immunotherapy) after surgery helps people with triple-negative breast cancer reduce the chance of the cancer coming back, compared with close monitoring only. It’s for patients who had no remaining invasive cancer after neoadjuvant chemotherapy plus pembrolizumab.
Birmingham, AlabamaAges 18 years+ - NCT06705127RecruitingPhase 2
Radiation, chemo, and immunotherapy for HR+ breast cancer
This trial tests if giving radiation first, then chemo with an immunotherapy drug called Toripalimab, can help treat a certain type of breast cancer that has not spread to other organs. It is for people with hormone receptor positive, HER2 negative breast cancer that is growing fast.
Hangzhou, ZhejiangAges 18–75
Hear when a new HER2-negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for her2-negative breast cancer?
- Yes. Clin2 currently lists 264 recruiting her2-negative breast cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a her2-negative breast cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a her2-negative breast cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Breast Cancer (Triple Negative Breast Cancer (TNBC))
- Breast Cancer Early Stage Breast Cancer (Stage 1-3)
- HR-positive, HER2-negative Advanced Breast Cancer
- Hormone Receptor Positive / HER2-negative Breast Cancer
- Metastatic Breast Cancer ( HER2 Negative)
- Triple Negative Breast Cancer
- HER2-positive Breast Cancer
- HR+/HER2- Breast Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.